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article under the CC BY-NC-ND licenseAbstract Objective: To better evaluate tertiary Gleason pattern reporting and to evaluate
the impact of tertiary Gleason pattern 5 (TP5) on prostate cancer pathological features and
biochemical recurrence at our large single institution.
Methods: We retrospectively reviewed 1962 patients who underwent radical prostatectomy
(RP) for prostate cancer; TP5 was reported in 159 cases (8.1%). Men with Gleason score (GS)
7 and GS 8 disease were divided into subgroups with and without TP5, and histopathological
features were compared. Multivariate analyses were conducted to assess the impact on TP5
on biochemical-free survival (BFS).
Results: Tumors possessing GS 3 þ 4 with TP5 were more likely to exhibit extraprostatic exten-
sion (EPE) and had a larger tumor diameter (TD) than GS 3 þ 4 alone. GS 3 þ 4 with TP5 was
also associated with positive surgical margins (SM), seminal vesicle involvement (SVI), and
higher pre-operative prostate-specific antigen (PSA) values, but without statistical signifi-
cance. GS 4 þ 3 with TP5 more commonly presented with EPE, positive SM, SVI, and greater
TD and pre-operative PSA level than GS 4 þ 3 alone. In multivariate analysis, Gleason score,h.edu (R. Mehra).
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54 Z.B. Koloff et al.EPE, and TP5 were overall independent risk factors for PSA recurrence in this cohort. Addition-
ally, GS 4 þ 3 with TP5 was associated with shorter time to recurrence versus GS 4 þ 3 alone.
Conclusion: Our results emphasize the importance of TP5 and suggest that criteria for tertiary
pattern reporting in prostate cancer should be standardized. Further studies are needed to
evaluate the role of tertiary patterns in prognostic models.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The original Gleason scoring system proposed that the
overall grade of prostate cancer was best determined by the
sum of the two most common architectural patterns of the
tumor [1e3]. The most prevalent pattern was described as
the primary grade and the secondmost prevalent pattern the
secondary grade. These primary and secondary patterns
have been well studied, and higher Gleason scores are
significantly associated with adverse pathological factors
(e.g., positive surgical margins [SM], seminal vesicle invasion
[SVI], lymph node involvement [LNI], and extraprostatic
extension [EPE]) and prostate-specific antigen (PSA) recur-
rence [1e3]. Over the years, the Gleason scoring system has
continued to demonstrate strong prognostic power [4e6].
Although Gleason scores or sums are typically reported
based on a combination of primary and secondary grades
(for example, 3 þ 4 Z 7), even in 1977 Donald Gleason
noted that “occasionally, small areas of a third pattern
were observed” [7]. Increasingly in recent years there has
been investigation into the criteria and relevance of this
third, “tertiary” Gleason component. Currently, however,
there is no consensus definition of this tertiary component.
Some pathologists might report a tertiary pattern (TP) as
any third most common architectural pattern, while others
only report a TP when it is higher grade than the two more
prevalent patterns [8e11]. Several authors have suggested
that TP should be reported if the area is higher grade and
comprises less than 5% of the tumor volume, and reported
as the secondary grade if it is more prevalent [12,13]. In
2005, an international consensus conference on urologic
pathology recommended that the tertiary grade should be
commented on in pathology reports, however, the specific
criteria for reporting TP were not addressed then [14].
Despite the variable TP definitions of previous studies,
some studies have demonstrated that high-grade TP is asso-
ciated with adverse tumor characteristics and biochemical
recurrence [11,12,15e17]. The current study was conducted
using a database of patients who underwent RP for clinically
localizedprostate cancer to better evaluateTPreporting and
to evaluate the impact of tertiary Gleason pattern 5 (TP5) on
tumor pathological features and biochemical recurrence in
this large single institution series.
2. Materials and methods
The studydatawere obtained retrospectively and analyzed in
accordance with University of Michigan Medical School’s
Institutional Review Board (IRB) approved protocol. All men
in this study underwent radical prostatectomy (RP) and allsurgical specimens were uniformly processed. The prostate
and seminal vesicles were fixed in formalin after inking the
outer surface. The most proximal urethra at the prostate
base and apical 3-mm were embedded on end after radial
sectioning in a cone-like fashion to assess the inked bladder
neck and apical margins. The remaining prostate was serially
sectioned from apex to base at 3-mm intervals and submitted
as quadrisected sections for examination. A subset of pros-
tatectomy tissues underwent tissueprocurement protocol for
research purposes. In such cases, all peripheral margins were
submitted from the procured sections to ensure a complete
evaluation of margins and EPE (including extracapsular
extension in any location and seminal vesicle invasion). Cases
were signed out by a spectrum of pathologists including
general surgical pathologists as well as sub-specialty trained
genitourinary pathologists. A tumor component was desig-
nated as TP5 if it constituted less than 10% of the tumor mass
by microscopic visual inspection (all cases where surgical
pathology reports stated a TP comprising less than 10% of the
tumor were included for this study). Small foci of a lower
tertiary grade pattern were not recorded in this series.
Biochemical recurrence was defined as any post-
operative elevation of PSA >0.2 ng/mL. There were
incomplete data regarding PSA follow-up for a small pro-
portion of patients (3%), therefore, these patients were
excluded in the analysis of PSA recurrence. The data
regarding which patients received adjuvant treatment
following RP were not consistently available.
Statistical analyses were performed using SAS program
version 9.3 (SAS Institute Inc., Cary, NC, USA) and MedCalc
version 12.7 (MedCalc Software, Ostend, Belgium). Uni-
variate analyses for subjects with and without tertiary
Gleason scores were based on chi-square and Fisher’s exact
tests for categorical variables, and t-tests and Wilcoxon
rank sums for continuous variables. Multivariate analyses
were performed using Cox Proportional Hazards Model. The
log rank test was used to compare KaplaneMeier proba-
bilities for PSA recurrence between subjects with and
without tertiary Gleason components. P-values <0.05 were
considered statistically significant.3. Results
We retrospectively reviewed RP pathology reports between
September 2005 and December 2012 to identify cases with
a reported tertiary Gleason component. This time period
was selected since the International Society of Urological
Pathology (ISUP) released a consensus statement in
September 2005 recommending that tumor grades be
assigned a Gleason score based on the primary and
Table 1 Distribution of Gleason scores.
Gleason score Tertiary pattern Number of cases
3 þ 4 Z 7 940
3 þ 4 Z 7 5 33
4 þ 3 Z 7 265
4 þ 3 Z 7 5 120
4 þ 4 Z 8 37
4 þ 4 Z 8 5 3
Total 1398
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Tertiary Gleason 5 and prostate cancer 55secondary patterns with a comment regarding the tertiary
score, if present [14]. However, without formal parameters
to guide tertiary Gleason component reporting, and since
the evaluation of involvement is subjective based on visual
inspection, there is some variability in the literature.
Among a total of 1962 RP specimens thatwere reviewed in
this study, 159 cases with TP5 were reported. Three pa-
thology reports included comments that the tertiary Gleason
5 component comprised approximately 15% of the index
tumor. These caseswith relatively large tertiary components
were excluded from our analysis based on previous studies
[12,13]. We set the cut-off point at 10% for our study and
hence all other cases that reported a tertiary component
remained in our analysis. These remaining 156 cases with
TP5 were analyzed compared to control patients with the
same primary and secondary Gleason patterns without ter-
tiary components. Among the cohort of patients with TP5,
majority of patients were histologically determined to have
either Gleason score 3þ 4 or 4þ 3 disease. The breakdown of
Gleason scores (GS) is detailed in Table 1.
General characteristics of all GS 7 and 8 patients
included in this study are presented in Table 2. Tumor
grades and histopathological characteristics are detailed in
Table 3. GS 3 þ 4 with TP5 tumors were significantly asso-
ciated with EPE and larger tumor diameters (TD) than GS
3 þ 4 alone (p < 0.0001 for both). GS 3 þ 4 with TP5 tumors
also tended to present with positive SM, LNI, SVI, and have
higher pre-operative PSA than GS 3 þ 4 tumors, but without
significance. GS 4 þ 3 with TP5 tumors were more likely to
demonstrate EPE, positive SM, SVI, have larger TD, andTable 2 Gleason 7 and 8 patient characteristics
(n Z 1398).
Variable Value
Age (years), mean  SD 60.7  7.1
Pre-operative PSA
Mean 7.10
Median 7.14
EPE, n (%) 257 (18.3)
SM, n (%) 235 (16.8)
SVI, n (%) 56 (4.0)
LNI, n (%) 13 (0.9)
Tumor diameter (mm)
Mean 1.70
Median 1.60
PSA, prostate-specific antigen; EPE, extraprostatic extension;
SM, surgical margins; SVI, seminal vesicle invasion; LNI, lymph
node invasion; Tumor diameter, maximum tumor diameter. T
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Table 4 Effect of various variables on biochemical
recurrence based on Cox Proportional Hazards Model.
Covariate HR 95%CI p-value
PSA (continuous) 1.02 1.01e1.03 <0.0001
Gleason score
GS 2-6 (reference)
GS 3 þ 4 1.70 0.63e4.40 0.31
GS 4 þ 3 6.30 2.50e16.30 <0.0001
GS 8-10 11.00 4.10e29.10 <0.0001
TP5
No (reference)
Yes 1.80 1.10e2.70 0.017
EPE
No (reference)
Yes 2.10 1.30e3.30 0.003
Positive SM
Negative (reference)
Positive 1.10 0.76e1.60 0.53
SVI
No (reference)
Yes 0.94 0.56e1.60 0.83
Node stage
Negative or n/a
(reference)
Positive 1.50 0.75e3.20 0.24
PSA, prostate-specific antigen; HR, hazard ratio; 95% CI, 95%
confidence interval; GS, Gleason score; TP5, tertiary Gleason
pattern 5; EPE, extraprostatic extension; SM, surgical margins;
SVI, seminal vesicle invasion.
56 Z.B. Koloff et al.present with higher pre-operative PSA levels than GS 4 þ 3
alone (p < 0.0001, p Z 0.02, p < 0.0001, p < 0.0001, and
p < 0.0001, respectively). GS 4 þ 3 with TP5 also tended to
present with LNI more often than GS 4 þ 3, but without
significance.
KaplaneMeier PSA recurrence-free survival curves for GS
3þ 4 and 4þ 3 patientswith andwithout TP5were compared
using log rank tests. When comparing GS 3 þ 4 patients to
those with GS 3 þ 4 with TP5, there was no significant dif-
ference in PSA recurrence-free survival, and only one pa-
tient with GS 3 þ 4 with TP5 recurred. However, there was a
shorter time to PSA recurrence among GS 4 þ 3 with TP5
patients compared to GS 4 þ 3 patients (pZ 0.005, Fig. 1).
Since TP5 was associated with other adverse pathologic
features, a multivariable analysis was performed to inves-
tigate whether TP5 was independently associated with
biochemical-free survival (BFS). Gleason score was cate-
gorized into four compartments (GS 26, 3 þ 4, 4 þ 3, and
8e10), as the majority of our patient population had GS 7
disease. When multivariate analysis of BFS was conducted,
the presence of TP5 was associated with decreased BFS
with an HR of 1.8 (95%CI: 1.12.7, pZ 0.017; Table 4). Pre-
operative PSA, GS, and EPE were also significant factors
related to PSA recurrence. However, in our patient popu-
lation, patients with GS 7 were the most likely to have TP5,
so we performed another multivariate analysis limited to
those patients (GS 3 þ 4 and GS 4 þ 3). Again, TP5 was an
independent risk factor for PSA recurrence with an HR of
1.9 (95%CI: 1.13.3, p Z 0.035; data not shown).
4. Discussion
The Gleason scoring system remains one of the most
important prognostic parameters for prostate cancer. Over
nearly 50 years, this grading system has remained largelyFigure 1 PSA recurrence-free survival in patients with Gleason s
score 4 þ 3 with TP5 disease. Log rank chi-square 7.80, p Z 0.005intact aside from minor modifications to adapt to changes
in the clinical practice of screening and management of
prostate cancer [4e6]. In 2005, the ISUP met to establish a
new consensus regarding prostatic carcinoma grading.core 4 þ 3 disease without a tertiary component and Gleason
.
Tertiary Gleason 5 and prostate cancer 57Among the debatable topics within the field of urologic
pathology is the presence of a tertiary architectural pattern
within a prostate specimen. For RP specimen, the ISUP
stated that “one assigns the Gleason score based on the
primary and secondary patterns with a comment as to the
tertiary pattern” [14].
However, to date, pathologists have variable criteria of
when to report this tertiary pattern. At our institution, TP5
was reported in 8.1% of pathology specimens. Although this
was a somewhat lower incidence compared to other studies
reporting TP5 in 10%e27% of cases, this may be reflective of
the variable interpretation of when to report a tertiary
pattern [12,16]. Some pathologists report the presence of
any Gleason pattern that is less prevalent than the primary
or secondary grades [8,10]. Others only report the third
most prevalent pattern if it is higher grade than the primary
and secondary patterns [11,15]. Recently, several authors
suggested that a tertiary Gleason pattern only be reported
if the area is higher grade than the primary and secondary
patterns, and the area comprises less than 5% of the tumor
volume [12,13,16]. In our current study, all cases where
comments reported a TP comprising less than 10% of the
tumor were included for this analysis.
In general, it is well established that the presence of a
high grade Gleason pattern is a poor prognostic indicator. In
fact, McNeal et al. [18,19] suggested modifying the Gleason
scoring system to include the proportion of high grade
(Gleason 4 or 5) cancer in a tumor specimen, as their studies
found poor architectural differentiation to correlate with
tumor volume, nodal metastasis, and tumor progression.
Similarly, Cheng et al. [20] concluded that the combined
percentage of Gleason patterns 4 and 5 was superior to
conventional Gleason scoring in predicting patient outcome
and PSA recurrence. Stamey and his colleagues [21] found
the percentage of Gleason grade 4 or 5 disease to be inde-
pendently associatedwith prostate cancer progression while
other common predictors of progression, such as positive
margins and capsular invasion, did not reliably predict
recurrence following RP. A recent study at our institution
found that the presence of Gleason pattern 5 was the single
strongest pathological predictor of recurrence, metastasis,
and prostate cancer-specific death in patients receiving
salvage radiation therapy following RP [22].
Several groups have investigated whether high grade
Gleason patterns are correlated with tumor aggressiveness
and poor outcomes, even when present in small amounts
and reported as a tertiary component. Similar to our study,
Mosse et al. [12] reported that Gleason 7 tumors with TP5
were more likely to be higher stage and have worse prog-
nostic clinico-pathological features. A systematic review
and meta-analysis on the significance of high grade TP
published in 2007 concluded that high tertiary grades were
associated with poorer outcomes [17]. However, that re-
view only included one study published after the ISUP
Consensus Conference on Gleason grading and the meta-
analysis failed to take into account the variable defini-
tions of the tertiary Gleason pattern. More recent studies
such as those by Turker et al. [15], Trock et al. [16], Pier-
orazio et al. [23], and Servoll et al. [24] concluded that
high-grade TP is important as an independent predictor of
PSA recurrence in Gleason 7 and 8 prostate cancers. In fact,
Nanda et al. [25] found the risk of PSA recurrence inpatients with Gleason 7 disease with TP5 to be similar to
patients with Gleason 9 or 10 diseases. In contrast to those
studies, others found that tertiary Gleason patterns were
not consistently independent predictors of PSA recurrence
[8,11].
In our study, Gleason 7 tumors with TP5 were more likely
to present at higher stages and have larger tumor di-
ameters. In the sub-group of GS 4 þ 3 tumors, those with
TP5 were also more likely to have positive SM, SVI, and
present with higher pre-operative PSA values than those
tumors with the same Gleason score without TP5. GS 3 þ 4
and 4 þ 4 tumors with TP5 also tended to present with
those worse clinico-pathological parameters and higher
pre-operative PSA levels, however, differences were not
statistically significant perhaps due to the relatively small
sample size in those subgroups.
In regards to BFS, as defined by undetectable PSA, TP5
was found to be an independent predictor of worse
outcome. GS 4 þ 3 with TP5 tumors demonstrated a shorter
time to recurrence compared to GS 4 þ 3 tumors. However,
GS 3 þ 4 with TP5 tumors did not significantly differ from GS
3 þ 4 tumors in terms of time to recurrence. Again, this may
be a reflection of the small number of patients with GS
3 þ 4 with TP5. Nevertheless, even when accounting for
these other pathologic and clinical features on multivariate
analysis, the presence of TP5 remained a strong prognostic
factor imparting a 1.8-fold increase in the risk of
biochemical recurrence.
In current practice, many clinicians rely on various tables
or algorithms, such as Partin tables and Kattan nomograms,
in order to predict pathological stage and outcomes and to
guide treatment strategies in prostate cancer [5,26]. How-
ever, when assessing tumor grades, the comments and notes
from pathological reports are often not included in prog-
nostic models. Therefore, although recent evidence seems
to suggest that a high-grade tertiary component worsens
prognosis in prostate cancer, that parameter is often dis-
missedwhen crucial decisions about cancermanagement are
made. The ISUP conference in 2005 acknowledged the
importance of high-grade tertiary patterns in RP specimens,
but did not propose any formal criteria for diagnosis and
simply recommended that its presence be commented upon.
Therefore, based upon our study we recommend the inclu-
sion of several concepts. Firstly, standardized criteria for TP
scoring needs to be established. Secondly, further prospec-
tive studies should be conducted to evaluate for the role of
tertiary Gleason components in multivariable predictive and
prognostic models.
There are some limitations to our study. One limitation is
its retrospective design. Additionally, despite the large
overall sample size, there were certain subgroups which
were relatively small and the power of analysis may have
been too low to detect small differences. We were not able
to compare the differences between patients with TP5
comprising less than 5% of the index tumor versus cases
where TP5 comprised less than 10% due to inconsistent
detail in pathology comments. However, during this time
period at our institution, Gleason pattern 5 in less than 10%
of the tumor was primarily used as the criteria for reporting
tertiary patterns. Another limitation of this study was that
we were not able to confidently report which patients
received salvage or adjuvant treatment after RP as some
58 Z.B. Koloff et al.patients may have received subsequent treatment at other
institutions, but were lost for primary follow-up at our
hospital. Based on our institutional experience, the number
of patients with Gleason 7 disease receiving adjuvant
therapy is very low, but this information was not reliably
available in our current dataset. It is also unusual that SVI,
LNI, and margin status were not predictive of biochemical
recurrence after prostatectomy at the multivariate level in
this cohort. We suspect that an interplay of factors
including strong influence of TP5, impact of unknown
adjuvant therapies, and a relatively small number of cases
might have influenced this pattern.
In conclusion, our study using a large population of pros-
tate cancer patientswho underwent RPat a single institution
with consistent pathologic evaluation demonstrates that
prostate cancer with TP5 is associated with aggressive fea-
tures and is an independent risk factor of biochemical
recurrence. Given the strong evidence that TP is a relevant
risk factor in prostate cancer, prospective studies are
needed to evaluate for the potential role of high-grade ter-
tiary patterns in prostate cancer prognostic models.
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